Ann Stem Cell Res Ther | Volume 3, Issue 2 | Case Report | Open Access

Probability of Chagas Reactivation Following Hematopoietic Stem Cell Transplantation (HSCT) on Maintenance Lenalidomide - Are there Guidelines for Active Surveillance?

Mridula Krishnan^1*, Andrea Zimmer² , Sarah Holstein¹ and Matthew Lunning¹

¹Department of Hematology and Oncology, University of Nebraska Medical Center, USA²Department of Infectious Disease, University of Nebraska Medical Center, USA

^*Correspondance to: Mridula Krishnan 

Abstract

Chagas Disease (CD) is an endemic disease in developing countries caused by Trypanosome cruzi (T.cruzi), which has been shown to have a chronic asymptomatic phase. However, immunosuppressed patients, particularly transplant recipients (both bone marrow and solid transplant), are at a risk of reactivation of CD which can be fatal. Our primary focus involves bone marrow transplant recipients with chronic CD. There is a lack of guidelines for surveillance of these patients. We sought guidance from the Center for Disease Control (CDC) for active surveillance. We present a case of a Hispanic female with chronic CD who was on maintenance Lenalidomide following autologous hematopoietic stem cell transplant for multiple myeloma.

Citation:

Krishnan M, Zimmer A, Holstein S, Lunning M. Probability of Chagas Reactivation Following Hematopoietic Stem Cell Transplantation (HSCT) on Maintenance Lenalidomide - Are there Guidelines for Active Surveillance?. Ann Stem Cell Res Ther. 2019; 3(2): 1031 .